FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial. PMID 41419618 · Diabetologia · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Long-term outcomes of S-1-based chemoradiotherapy in inoperable elderly patients with esophageal carcinoma: A multicenter, randomized, phase III clinical trial. PMID 41412437 · Radiother Oncol · 2026-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Pridopidine treatment in ALS: subgroup analyses from the HEALEY ALS Platform trial. PMID 41406304 · Amyotroph Lateral Scler Frontotemporal Degener · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies. PMID 41401055 · J Eur Acad Dermatol Venereol · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Surgical excision versus topical 5% 5-fluorouracil and photodynamic therapy in the treatment of Bowen's disease: Long-term results of a multicenter randomized controlled trial. PMID 41391634 · J Am Acad Dermatol · 2026-May The study is a randomized, multicenter trial with a primary time-to-event endpoint (tumor-free survival) and includes a drug intervention (5-fluorouracil). However, it is not explicitly identified as a Phase III or definitive trial, and the condition (Bowen's disease) is a non-metastatic skin lesion, making it a borderline oncology context. The primary endpoint, while time-to-event, is not a standard oncologic efficacy endpoint like OS, PFS, or DFS for advanced disease. The deterministic review correctly flagged the lack of clear phase and standard time-to-event signal. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety of a group B Streptococcus vaccine (GBS-AlpN) in pregnant women and their infants: a phase 2, multicentre, observer-blind, randomised, placebo-controlled study. PMID 41386262 · Lancet Infect Dis · 2026-May 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Lobaplatin versus cisplatin in concurrent chemoradiotherapy for elderly cervical cancer: randomized controlled phase II study. PMID 41381401 · J Gynecol Oncol · 2026-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: Updated systematic review, individual-patient-data meta-analysis and trial sequential analysis of randomized controlled trials. PMID 41381268 · Surgery · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial. PMID 41364813 · J Urol · 2026-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years. PMID 41239921 · J Eur Acad Dermatol Venereol · 2026-May The study is a randomized, Phase 3 trial of upadacitinib, but it is for atopic dermatitis (non-oncology) and is a safety analysis, not an efficacy analysis with a primary time-to-event endpoint. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68-week randomized Phase 3 trial. PMID 41239899 · J Eur Acad Dermatol Venereol · 2026-May 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial. PMID 41223900 · Ophthalmology · 2026-May 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy of up to 4 years of tralokinumab in adults with moderate-to-severe atopic dermatitis. PMID 41217071 · J Eur Acad Dermatol Venereol · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A randomized study comparing outcomes of intravesical Gemcitabine, Mitomycin C (as hyperthermic intravesical chemotherapy-HIVEC) and Bacillus-Calmette Guerin in intermediate and high-risk non-muscle invasive bladder cancer. PMID 41216726 · Urologia · 2026-May Eligibility cannot be confirmed because the trial phase (Phase III/IIIb or Phase II/III) is not explicitly established in the provided record. While the study is an original randomized trial with a time-to-event endpoint and drug intervention, the 'preliminary findings' and 'limited sample size' noted in the conclusion, combined with the lack of a clear phase designation, prevent definitive inclusion. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Endoscopic ultrasound-guided transpapillary versus transluminal biliary stenting: randomized comparison of long-term stent patency. PMID 41077045 · Endoscopy · 2026-May 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Acoltremon Ophthalmic Solution 0.003% for Signs and Symptoms of Dry Eye Disease: Results of Phase 3 Pivotal COMET-2 and COMET-3 Studies. PMID 41038456 · Ophthalmology · 2026-May 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Fluid/function correlation using AI-based quantification versus central subfield thickness in treatment-naïve and pre-treated patients with neovascular AMD in a real-world setting. PMID 40965041 · Acta Ophthalmol · 2026-May 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of Extended Risankizumab Treatment in Patients With Ulcerative Colitis Who Did Not Respond to Induction Treatment. PMID 40953785 · Clin Gastroenterol Hepatol · 2026-May 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint Inhibitors. PMID 40658913 · JCO Oncol Pract · 2026-May 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligibleexplicit_phase3_randomized | needs_review 1 Figure · 1 Panel · risk unclear |
| The Effect of Cognitive Behavioral Therapy-Based Psychoeducation on Anger Management and Death Anxiety in Individuals Receiving Chemotherapy: A Randomized Controlled Trial. PMID 38517134 · Omega (Westport) · 2026-May The study is a randomized trial in oncology patients, but it evaluates a psychoeducational intervention (CBT-based), not a drug. It also does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The phase is not specified as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Pelubiprofen for Primary Dysmenorrhea: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Trial. PMID 41976959 · J Clin Med · 2026-Mar-31 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Concurrent chemoradiotherapy plus nimotuzumab versus chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma with a suboptimal response to induction chemotherapy: a randomized phase 2 trial. PMID 41916997 · Nat Commun · 2026-Mar-31 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| RETRACTION: Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8). PMID 41916660 · BMJ · 2026-Mar-31 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| CORRECTION: Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8). PMID 41916658 · BMJ · 2026-Mar-31 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trial. PMID 41916649 · BMJ · 2026-Mar-31 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 1 Figure · 4 Panel · risk unclear |
| Effect of Finerenone Treatment Discontinuation on Kidney and Cardiovascular Outcomes: A Fidelity Analysis. PMID 41915602 · Am J Nephrol · 2026-Mar-31 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Development of the Healthy Women Intervention to Increase Women's Engagement in Medication Treatment for Opioid Use Disorder: Mixed Methods, User-Centered Design Approach. PMID 41915447 · JMIR Form Res · 2026-Mar-31 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The use of endpoints in phase 3 randomized controlled trials in metastatic breast cancer. PMID 41915264 · Breast Cancer Res Treat · 2026-Mar-31 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Perineal versus retropubic radical prostatectomy in localized prostate cancer: extended analysis of a prospective randomized cohort. PMID 41914230 · Arch Ital Urol Androl · 2026-Mar-31 The study is an oncology, human, randomized, original result report with a time-to-event endpoint (BCRFS). However, it does not involve a drug-containing intervention (it compares surgical techniques) and the phase of the trial is not specified as Phase III/IIIb or Phase II/III. Therefore, it is excluded based on the lack of a drug intervention and definitive phase evidence. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Aspirin in Colorectal Cancer Care: Who to Treat, When, and Why. PMID 41912748 · Curr Oncol Rep · 2026-Mar-31 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Safety and Immunogenicity of a Sabin Strain-Based Inactivated Polio Vaccine: A Phase III, Randomized, Blinded, Positive-Control Clinical Trial in Infants Aged Two Months. PMID 42042788 · Vaccines (Basel) · 2026-Mar-30 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial. PMID 42017875 · J Am Coll Cardiol · 2026-Mar-30 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Metformin Repurposing in Neurological Disorders: A Clinical Trial Landscape. PMID 41930282 · Ann Neurosci · 2026-Mar-30 The record is a systematic review of the clinical trial landscape for metformin repurposing in neurological disorders, not an original report of a randomized trial in oncology. It does not contain results from a specific Phase III/IIIb or Phase II/III trial with a drug-containing intervention and a time-to-event efficacy endpoint. Therefore, it is ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Temporary interruption versus maintenance of anticoagulation in polypectomy of colorectal lesions: study protocol for a multicentre randomised non-inferiority clinical trial POLYPHEM. PMID 41916623 · BMJ Open · 2026-Mar-30 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Baricitinib in moderate to severe rheumatoid arthritis: dose-dependent efficacy and safety in a randomized clinical trial in a developing country. PMID 41913302 · BMC Rheumatol · 2026-Mar-30 The study is a randomized, drug-intervention trial with original results, but it is not an oncology study; it is for rheumatoid arthritis. Therefore, it does not meet the oncology requirement for the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Self-amplifying COVID-19 mRNA vaccination induces longitudinally enhanced antibody function in a Phase 3 trial. PMID 41912532 · NPJ Vaccines · 2026-Mar-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Results of the AiM, PLan, and act on LIFestYles (AMPLIFY) Weight Loss Intervention Among Survivors of Obesity-Related Cancers: A Randomized Clinical Trial. PMID 41911893 · J Natl Compr Canc Netw · 2026-Mar-30 The study is a randomized trial in cancer survivors but fails two key eligibility criteria: (1) it evaluates a lifestyle/diet intervention, not a drug-containing intervention, and (2) its primary efficacy endpoint is weight loss (a continuous measure), not a time-to-event endpoint (like OS, PFS, DFS) analyzed via Kaplan-Meier or hazard ratios. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Motor Imagery and Action Observation in Breast Cancer Survivors: Protocol for a Randomized Controlled Trial. PMID 41911468 · JMIR Res Protoc · 2026-Mar-30 This is a protocol for a randomized controlled trial evaluating a non-drug rehabilitation intervention (motor imagery/action observation) in breast cancer survivors. It lacks a drug intervention, a time-to-event endpoint, and any trial results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer. PMID 41910867 · Breast Cancer Res Treat · 2026-Mar-30 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Targeting the Unmet Need in Gastrointestinal Stromal Tumors: A Contemporary Review of Investigational Clinical Trials and Therapeutic Landscape. PMID 42075805 · Pharmaceuticals (Basel) · 2026-Mar-29 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy. PMID 41910394 · N Engl J Med · 2026-Mar-29 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of concurrent chemotherapy dose on long-term survival in locally advanced nasopharyngeal carcinoma: a 10-year single-center study. PMID 41904463 · BMC Cancer · 2026-Mar-28 The record does not explicitly establish that this is a Phase III, Phase IIIb, or Phase II/III trial. All other eligibility criteria (oncology, human, randomized, time-to-event endpoint, drug intervention, original result) are met. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial. PMID 41904192 · Nat Commun · 2026-Mar-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, randomised controlled trial. PMID 41875914 · Lancet · 2026-Mar-28 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial. PMID 41763229 · Lancet · 2026-Mar-28 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Global landscape of yttrium-90 clinical trials: a systematic registry-based analysis. PMID 41896975 · Trials · 2026-Mar-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma. PMID 41896823 · BMC Cancer · 2026-Mar-27 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution in Children and Adolescents: An 8-Week Phase 3 Study. PMID 41891657 · J Investig Allergol Clin Immunol · 2026-Mar-27 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Interactive symptom monitoring and coaching to optimise toxicity management of chemo(immune)therapy in early stage breast cancer: study protocol of the multicentre randomised controlled eChemoCoach trial. PMID 41888754 · BMC Cancer · 2026-Mar-26 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Study protocol for hyperthermic intraperitoneal chemotherapy in the treatment of locally advanced gastric cancer after laparoscopic or robotic Gastrectomy with D2 lymphadenectomy: a phase III multicentre prospective randomized controlled clinical trial (HIPEC-09). PMID 41888710 · BMC Cancer · 2026-Mar-26 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |